COPD

In this interview, Han highlighted new information included in the GOLD 2025 Report regarding utilization of dupilumab and ensifentrine for certain patients with COPD.

In these updates and new sections, the 2025 GOLD report included highlighted climate change, cardiovascular risk, and pulmonary hypertension.

A trio of stakeholders join Lungcast to discuss the ongoing, long-term assessment into the patterns and drivers of chronic lung disease in a real-world cohort.

Antonio Anzueto, MD, discusses how dupilumab fits into treatment algorithms for patients with uncontrolled COPD.

Stephanie Christenson, MD, discusses the impact of recent regulatory approvals and pipeline movement for chronic obstructive pulmonary disease.

New research presented at CHEST 2024 highlights ensifentrine’s effectiveness in improving lung function, symptoms, and quality of life for COPD patients, regardless of disease severity.

The latest episode of Lungcast explores the evolving field of pulmonary imaging technology and the transformative impact of artificial intelligence.

This approval by the FDA follows positive findings from the pivotal BOREAS and NOTUS trials on adults with uncontrolled COPD.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

This model and its service components may be implemented in the future to allow for improvements to primary care programs, with the goal being benefits to patients with COPD.

In this summary of major news in pulmonology covered in June 2024, approvals by the FDA, new episodes of Lungcast, news on COPD, and more are highlighted.

The panel concludes the discussion with key takeaways on the evolving treatment landscape for COPD.

Experts on respiratory diseases discuss the role of primary care providers in the treatment of patients with COPD.

Mannino, Anzueto and Christenson conclude the panel with thoughts on developing biologics for COPD, and increased interest in the field after ensifentrine and dupilumab.

Ahead of the anticipated FDA decision in September, an expert panel reviews the promising data and unique role dupilumab may have in COPD.

In this HCPLive Special Report, experts review ensifentrine's role as a novel maintenance therapy for COPD.

Ensifentrine, a PDE3 and 4 inhibitor from Verona Pharma, was associated with significantly improved lung function and reduced COPD exacerbations over 24 weeks.

Clinical insights on the relationship between comorbidities in COPD and how multimorbidity plays a role in treatment decisions.

Focusing on evolving therapeutic paradigms for patients with COPD, experts discuss the importance of earlier diagnosis and treatment.

Experts share perspectives on the future treatment landscape for patients with COPD, highlighting the importance of precision medicine and the remaining unmet needs.

The panel discusses emerging treatment approaches in COPD and reviews the study design and topline results from the BOREAS trial investigating dupilumab.

These data indicate the benefits of implementing individual protective measures in winter by patients with COPD.

Igor Barjaktarevic, MD, PhD, discusses the evolving treatment landscape in COPD, highlighting current treatment approaches and novel therapies on the horizon.

Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.

Focusing on the role of eosinophils in diagnosing COPD, the panel discusses how often they should be tested, the cut-off value, and the natural changes of eosinophils in the disease course.